This clinical trial is focused on studying breast cancer, specifically advanced stages of the disease. The treatment being tested is a medication called Talazoparib, which is taken in the form of hard capsules. Talazoparib is a type of drug known as a PARP inhibitor, which works by interfering with cancer cells’ ability to repair themselves, potentially slowing down or stopping their growth.

The purpose of the study is to determine if a test called the RECAP test can help identify patients who are more likely to benefit from treatment with Talazoparib. The study will involve patients with advanced breast cancer, including those with specific types of the disease, such as ER-positive and HER2-negative breast cancer, as well as triple-negative breast cancer. The trial will also include patients with certain genetic mutations, like BRCA1 and BRCA2, which are known to affect how breast cancer develops and responds to treatment.

Participants in the study will receive Talazoparib and will be monitored over a period to see how their cancer responds to the treatment. Some patients may receive a placebo instead of the actual medication. The main goal is to see how many patients experience a period of time without their cancer getting worse, known as progression-free survival, for at least four months. The study will also look at other outcomes, such as overall response to the treatment and overall survival rates among participants.